Manufacturing Matters in Cell Therapy
Cell and gene therapy represent a new human health paradigm, with the potential to provide curative solutions rather than just chronic treatments for a variety of human diseases and genetic disorders. Rapid growth in the cell therapy industry is driving demand for cellular manufacturing, a process that can make or break the commercial success of a clinically promising cellular therapeutic.
In this report we highlight key factors that influence manufacturing decisions, discuss elements essential to the success of current leaders in cell production, and provide competitive intelligence on large and small scale automated manufacturing systems. We analyze market trends in the cell therapy industry, revealing near-term opportunities for cell therapy companies, as well as market entrance and adoption strategies for providers of products and services for cell manufacturing.
CAR-T Deal Review
In 2012, the striking clinical success of CAR-T therapy in treating acute lymphoblastic leukemia (ALL) in the case of Emily Whitehead was a real game changer for the industry. Since then, there has been an explosion of commercial activity.
In this CAR-T Deal Review we have captured the number and diversity of deals done in this space over the past four years. Included are strategic partnerships, acquisition and licensing deals done between CAR-T companies, Big Pharma, smaller organizations, and academic institutions from 2012 through August 2016. These deals cover intellectual property, new approaches for creating CARs using gene-editing technologies, expansion to allogeneic approaches, manufacturing, combination therapies, and more.